The Daily Fuckup

DermTech, the skin-cancer testing company that is now operating as DTech Liquidating Inc., has agreed to pay up to $5.038 million to resolve federal allegations that it billed Medicare for unreliable tests while knowing its quality-control system had problems. The settlement, announced Wednesday, August 26, is tied to claims that the company submitted false claims for one of its skin-cancer tests even though it had not properly validated a positive control range for a key melanoma marker. In plain terms, federal officials say the company kept charging a public health program for diagnostics that were not meeting the standards they were supposed to meet. The case is especially awkward because it sits at the intersection of medical testing, taxpayer money, and bankruptcy court, three places where “we’ll fix it later” is not exactly a reassuring motto. And while a settlement is not the same thing as a courtroom finding of liability, the size and structure of the deal suggest the government believed it had enough to press the issue rather than let it drift into the slow, expensive fog of litigation.

The basic allegation is straightforward even if the underlying science is not. According to the government, DermTech used an unvalidated positive control range for one of the test’s important melanoma markers, meaning it continued operating and billing while the test’s reliability was in question. That matters because Medicare does not exist to subsidize hopeful guesses dressed up as lab work. It exists to pay for care that is supposed to be dependable, and diagnostic testing is one of the places where errors can have consequences long before anyone notices a problem in the paperwork. A false negative can delay treatment, while a false positive can send patients into a spiral of unnecessary follow-up testing, anxiety, and cost. When the alleged misconduct involves a cancer-related test, the stakes are not abstract, because the whole point of screening is to catch trouble early enough to matter. Federal officials say the company’s billing went forward anyway, which is why this case has the flavor of a compliance failure that crossed the line into fraud. If the government’s account is accurate, the issue was not merely that the company encountered technical trouble, but that it allegedly kept treating those troubles as somebody else’s problem while Medicare covered the bill.

The bankruptcy backdrop makes the whole thing even messier, and not in a way that comforts taxpayers. The company’s financial distress means the government’s recovery may be limited by the bankruptcy process, which is where big claims often go to get sorted, delayed, and partially paid if they are lucky. That is why the announced figure is framed as “up to” $5.038 million rather than a clean, no-strings-attached payout. Bankruptcy can turn a case like this into a frustrating accounting exercise, where the principle of accountability remains intact but the dollars arrive in a diminished, bureaucratic form. For anyone following the recurring saga of health-care enforcement, this is a familiar pattern: alleged misconduct occurs, regulators and prosecutors intervene later, and the company’s finances are often too damaged to make the resolution feel proportionate to the harm. That does not make the settlement meaningless, but it does mean the remedy may look less like a full reckoning and more like a negotiated salvage operation. In a better world, the testing problems would have been fixed before the billing, not after the company was already headed toward liquidation.

Still, the government will almost certainly point to the case as another example of why fraud enforcement in health care keeps getting attention. Settlements like this are useful to prosecutors because they produce a concrete outcome that can be held up as evidence of vigilance, even when the underlying losses and patient risks are harder to quantify. The broader lesson is less flattering: private companies sometimes push ahead when their internal controls are shaky, public programs end up absorbing the risk, and the final cleanup arrives only after the damage has been baked into years of claims and accounting. That is not a uniquely DermTech problem, but it is a highly visible version of a much larger one. Skin-cancer testing is a serious business, and the public has a right to expect that a company billing Medicare for those tests has done the work to make sure the results are scientifically sound. Whether this settlement closes the book or merely closes one chapter, it underscores the same ugly point: if the allegations are true, the company turned a quality-control problem into a reimbursement problem, and then turned that into a fraud case. For prosecutors, that is the kind of narrative they like to showcase. For everyone else, it is another reminder that the cost of sloppy medical billing is rarely limited to the balance sheet.